Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
9 of the most interesting biotech bosses in the game today: part 1
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Biotech exec pay — are they delivering returns that equal their pay packets?
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
Health: Botanix shares fall 50% after failed clinical trial
Health & Biotech
Health: Noxopharm reckons its cancer-fighting Veyonda treatment could be a winner for late-stage patients
Health & Biotech
Dr Boreham’s Crucible: Suda shows far more promise than its ‘penny-dreadful’ status suggests
News
Short & Caught: The stocks investors are shorting right now
News
Short & Caught: The ASX stocks investors are shorting right now
News
Corporate: Aguia directors take issue with the recent attempt to remove them
Health & Biotech
Imugene’s gastric cancer drug clears first safety hurdles
Health & Biotech
Imugene appoints scientific advisor to tackle gastrointestinal cancer
Health & Biotech
Why Imugene has a fighting chance in its cancer battle
Health & Biotech